ENROLLMENT CONTINUES IN VOYAGER'S ALADDIN TRIAL

Enrollment in Voyager's ALADDIN VP-AD-301, the first Phase III clinical trial investigating the safety and efficacy of VP4896 in the treatment of mild-to-moderate Alzheimer's disease, has passed its midpoint ahead of schedule, the company has reported. Voyager initiated enrollment in September 2005 and expects to complete enrollment of all 555 subjects before the end of this year.

Patients being recruited into the study are 60 years of age or older with mild to moderate Alzheimer's disease and have been taking Aricept, Exelon, Razadyne or Cognex for at least four months.